摘要 |
<p>compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: X is S, 0, or NH; "a" is a single bond; or "a" is a double bond and one of R<3> and R<4> and one of R<5> and R<6 >are absent; R<1> is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, S02-alkyl, C02R<13> and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R<8> and R<9>; R<2> is H, R<8> , or an alkyl group optionally substituted with one or more R<8> groups; R<3> , R<4>, R<5>, and R<6> are each independently selected from H, R<8> , an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R<8 >groups; or R<3> and R<4>, and/or R<5> and R<6> together represent =0; R<7> is H, R<8>, NH(CH2)nR<9>, CO(CH2)nR<9>, NHCO(CH2)nR<9>, O(CH2)nR<9>, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R<8 >and R<9>; R<8 >is OR<10>, NR<10>R<11>, halogen, CF3, N02, COR<10>, CN, COOR<10>, CONR<10>R<11>, S02R<10> or S02NR<10>R<11>; R<9 >is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, 0 and S, and optionally substituted with one or more R<8> groups; R<10>, R<11>, R<12> and R<13> are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula (1), and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.</p> |
申请人 |
CYCLACEL LIMITED;MCINNES, CAMPBELL;THOMAS, MARK;WANG, SHUDONG;MCINTYRE, NEIL;WESTWOOD, NICHOLAS;FISCHER, PETER |
发明人 |
MCINNES, CAMPBELL;THOMAS, MARK;WANG, SHUDONG;MCINTYRE, NEIL;WESTWOOD, NICHOLAS;FISCHER, PETER |